Sab biotherapeutics granted fast track designation from fda for sab-176 influenza immunotherapy with high cross-reactivity to multiple strains of influenza

Sioux falls, s.d., april 13, 2023 (globe newswire) -- sab biotherapeutics (nasdaq: sabs), (sab), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human, multi-epitope binding immunoglobulin (higg) antibodies, without the need for human donors, announced today that the us food and drug administration (fda) has granted fast track designation for sab-176, an investigational therapeutic for type a and type b influenza illness in high-risk patients, including those who have anti-viral resistant strains. the fast track designation is designed to facilitate accelerated development and expedited review of medicines that treat critical illnesses and address an unmet medical need, with the goal of having promising treatments reaching approval and patients as quickly as possible.
SABS Ratings Summary
SABS Quant Ranking